Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

Geron Corp (GERN)

Pharmaceutical Preparations

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

919 EAST HILLSDALE BOULEVARD, SUITE 250
FOSTER CITY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/31/1996

Market Cap

2,748,749,760

Shares Outstanding

543,060,000

Weighted SO

543,063,950

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

VKTX --.--%

TGTX --.--%

XFOR --.--%

PDSB --.--%

MDGL --.--%

ZURA --.--%

ENVB --.--%

EFTR --.--%

Beta

0.4770

Last Div

0.0000

Range

1.64-5.34

Chg

0.1000

Avg Vol

12125661

Mkt Cap

2748749760

Exch

NASDAQ

Country

US

Phone

650 473 7700

DCF Diff

4.5733

DCF

-0.0335

Div Yield

0.0000

P/S

2002.0027

EV Multiple

-12.0029

P/FV

9.7224

Div Yield %

0.0000

P/E

-13.5813

PEG

-1.0050

Payout

0.0000

Current Ratio

3.6054

Quick Ratio

3.5980

Cash Ratio

1.1403

DSO

831.0197

DIO

9.2968

Op Cycle

840.3164

DPO

67.5036

CCC

772.8128

Gross Margin

-21.1326

Op Margin

-165.5994

Pretax Margin

-159.9068

Net Margin

-159.9068

Eff Tax Rate

-0.0007

ROA

-0.4885

ROE

-0.7379

ROCE

-0.6574

NI/EBT

1.0000

EBT/EBIT

0.9656

EBIT/Rev

-165.5994

Debt Ratio

0.1878

D/E

0.2752

LT Debt/Cap

0.1064

Total Debt/Cap

0.2158

Int Coverage

-616.1734

CF/Debt

-2.4511

Equity Multi

1.4653

Rec Turnover

0.4392

Pay Turnover

5.4071

Inv Turnover

39.2610

FA Turnover

0.2830

Asset Turnover

0.0031

OCF/Share

-0.3164

FCF/Share

-0.3180

Cash/Share

0.5564

OCF/Sales

-150.6686

FCF/OCF

1.0052

CF Coverage

-2.4511

ST Coverage

-4.3207

CapEx Coverage

-192.0780

Div&CapEx Cov

-192.0780

P/BV

9.7224

P/B

9.7224

P/S

2002.0027

P/E

-13.5813

P/FCF

-13.2186

P/OCF

-14.4141

P/CF

-14.4141

PEG

-1.0050

P/S

2002.0027

EV Multiple

-12.0029

P/FV

9.7224

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 05, 22:22 GERN DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action – GERN GlobeNewswire Inc. May 02, 23:45 GERN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit GlobeNewswire Inc. Apr 29, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Geron, enCore, and TFI and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 28, 22:50 Geron Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. May 12 2025 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Apr 27, 20:14 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Canopy Growth Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CGC GlobeNewswire Inc. Apr 22, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Geron, enCore, and TFI and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 19, 16:34 GERN Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds Geron Corporation (GERN) Shareholders of Securities Fraud Class Action Lawsuit Deadline GlobeNewswire Inc. Apr 16, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Geron, enCore, and TFI and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 07, 22:02 Class Action Reminder for GERN Investors: Kessler Topaz Meltzer & Check, LLP Reminds Geron Corporation (GERN) Investors of Securities Fraud Class Action Lawsuit GlobeNewswire Inc. Apr 06, 14:10 ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN GlobeNewswire Inc. Apr 02, 22:00 GERN INVESTOR ALERT: Kirby McInerney LLP Notifies Geron Corporation Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit GlobeNewswire Inc. Mar 30, 23:02 GERN Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges GERN Investors with Losses to Contact the Firm PennyStocks Dec 15, 10:48 Penny Stocks To Buy? 4 To Watch Before Next Week The Motley Fool Nov 02, 16:30 Geron (GERN) Q3 2023 Earnings Call Transcript

Revenue Product Segmentation